This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus (LEGEND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05232071
Recruitment Status : Recruiting
First Posted : February 9, 2022
Last Update Posted : November 7, 2023
Information provided by (Responsible Party):
Inventiva Pharma

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 30, 2023
Estimated Study Completion Date : December 31, 2023